File downloaded on 2026-11-20
Source URL: https://medicines.health.europa.eu/veterinary/en/600000031482

EMDOFLUXIN 50 MG/ML SOLUTION FOR INJECTION FOR CATTLE, HORSES AND PIGS

Authorised

- Flunixin meglumine

Product identification

Medicine name:
EMDOFLUXIN 50 MG/ML SOLUTION FOR INJECTION FOR CATTLE, HORSES AND PIGS

Active substance:
Flunixin meglumine

Target species:
Cattle
Pig
Equid

Route of administration:
Intramuscular use
Intravenous use

Product details

Active substance and strength:
Flunixin meglumine

83.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Cattle**
  - Meat and offal. 31 day
  - Milk. 36 hour
- **Pig**
  - Meat and offal. 24 day

Intravenous use:

- **Cattle**
  - Meat and offal. 4 day
  - Milk. 24 hour
- **Equid**
  - Meat and offal. 5 day
  - Milk. no withdrawal period

Milk: Not authorised for use in mares producing milk for human consumption.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QM01AG90

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Available in:
Germany

Package description:
Available only in French
Available only in French
Available only in French

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Emdoka

Marketing authorisation date:
30/06/2020

Manufacturing sites for batch release:
Produlab Pharma B.V.

Responsible authority:
Federal Office Of Consumer Protection And Food Safety

Authorisation number:
402685.00.00

Date of authorisation status change:
30/06/2020

Reference member state:
France

Procedure number:
FR/V/0417/001

Concerned member states:
Austria Belgium Bulgaria Croatia Denmark Estonia Germany Hungary Ireland Italy Latvia Lithuania Luxembourg Netherlands Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 13/03/2026
Download

eu-puar-frv0417001-mr-rpe564-en.pdf